TRISTAN

Imaging biomarkers (IBs) for safer drugs: validation of translational imaging methods in drug safety assessment

FACTS & FIGURES

Start Date
End Date
Grant agreement number
116106

Contributions
IMI Funding
12 073 102
EFPIA in kind
10 448 317
Other
192 732
Total Cost22 714 151

Summary

Imaging techniques such as positron emission tomography (PET), computed tomography (CT), and magnetic resonance imaging (MRI) are widely used in medicine to diagnose diseases and track how well a patient is responding to treatment. However, imaging biomarkers based on these techniques are not yet widely used in the drug discovery process, although their non-invasive nature means they offer high-resolution insights into toxicity issues early on in drug development. The TRISTAN project brings together academics, small biotechs, imaging and pharmaceutical companies with the goal of validating the use of imaging biomarkers to assess and predict the toxicity of potential medicines on the liver and lungs. It will also improve the use of imaging to avoid side-effects which arise when certain types of drugs, such as therapeutic antibodies, go to the wrong part of the body. The imaging biomarkers will help translate pre-clinical (animal) findings to healthy volunteers and patients, and clinical trial findings to real-world patients, improving the success of drug development.

Participants Show participants on map

EFPIA companies
  • AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany
  • Bayer AG, Berlin, Germany
  • Bruker BioSpin MRI GmbH, Ettlingen, Germany
  • GE Healthcare Ltd, Little Chalfont, United Kingdom
  • Glaxosmithkline Research And Development LTD, Brentford, Middlesex, United Kingdom
  • Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, United States
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Chalmers Tekniska Hoegskola AB, Goeteborg, Sweden
  • European Organisation for Research and Treatment of Cancer, Brussels, Belgium
  • Lunds Universitet, Lund, Sweden
  • Stichting Katholieke Universiteit / Radboud university medical center, Nijmegen, Netherlands
  • The University of Manchester, Manchester, United Kingdom
  • The University of Sheffield, Sheffield, United Kingdom
  • University of Leeds, Leeds, United Kingdom
  • Université de Bourgogne, Dijon, France
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Antaros Medical AB, Mölndal, Sweden
  • Bioxydyn Limited, Manchester, United Kingdom
  • Truly Labs AB, Lund, Sweden
Third parties
  • Centre National De La Recherche Scientifique, Paris, France
  • University Hospital of South Manchester Foundation Trust, Wythenshaw, United Kingdom

CONTACT

Project coordinator
Yan Liu
European Organisation for Research and Treatment of Cancer
yan.liu[at]eortc.be
Project e-mail
contact[at]imi-tristan.eu